Researchers have genetically altered pancreatic ductal cells to produce and release insulin in response to elevated blood sugar, potentially offering a long-term treatment or cure for diabetes. The breakthrough, published in Science Translational Medicine, involved silencing a single gene to transform cells already present in the pancreas into insulin-producing beta-like cells. Among people with diabetes, beta cells—the primary insulin producers—are either absent or don't function properly, and the human pancreas typically contains about a billion of them.
The team used a genetic screen to identify which genes drive the natural but rare transformation of ductal cells into beta cells. Without genetic modification, fewer than 1 percent of ductal cells spontaneously adopted a beta-cell-like state, but when the researchers turned off a gene called ALDH3B2, that rate jumped to roughly 8.5 percent. The initial experiments used human cells in laboratory dishes, which were then transplanted into diabetic mice. Human insulin started circulating in the animals, and their glucose levels fell to near-normal ranges. These results lasted for six weeks.
According to Jian Li, a postdoctoral researcher at Harvard Medical School who led the study, scientists previously had no understanding of what genes controlled this cell transformation. The genetic screen approach involves breaking small sections of DNA across the genome to determine which are crucial for a specific biological process—similar to removing individual parts from a car engine to learn which components matter for fuel delivery or steering. The researchers chose ductal cells because earlier studies had found they occasionally transform into beta cells on their own, an uncommon occurrence among cells in adult bodies, which typically remain locked into their identities.
This strategy of harnessing existing pancreatic cells and altering their function by switching off genetic controls differs from other emerging treatments that create new insulin-producing cells in laboratories and then transplant them into patients. Those transplant-based approaches carry risks, particularly triggering immune system reactions. The new method faces its own obstacles, especially ensuring only the intended cells are edited, since ALDH3B2 is used by many cells throughout the body beyond just the pancreas. A major unanswered question remains: how does this gene participate in converting ductal cells into beta cells? Li said verifying that mechanism comes first, followed by exploring either gene therapy or finding specific small molecules to block this gene and determine if similar or superior results are achievable. Even modest improvements could dramatically affect the estimated 830 million people worldwide living with diabetes, including many who die annually from related complications. For pharmaceutical companies and biotech investors, the choice between developing precision gene-editing therapies versus small-molecule drugs will shape not just clinical timelines but also the competitive landscape for who controls the next generation of metabolic medicine.